MannKind Corp 2021 SR
The report outlines MannKind's ESG approach through 2021, focusing on its mission to provide innovative medicines for endocrine and orphan lung diseases. Key highlights include a 45% increase in headcount to 349 employees and achieving 33% female representation on the Board of Directors. The company emphasizes ethical conduct, product accessibility through programs like AfrezzaAssist, and environmental stewardship at its LEED Silver certified California office and Danbury manufacturing facility. It also details efforts in diversity and inclusion, with 43% of the workforce identifying as female.
Company: MannKind Corp
Sector: Health Care
Country: United States
Year: 2021
Type: SR
Pages: 23
Back to company
MannKind Corp
ESG Report
The report outlines MannKind's ESG approach through 2021, focusing on its mission to provide innovative medicines for endocrine and orphan lung diseases. Key highlights include a 45% increase in headcount to 349 employees and achieving 33% female representation on the Board of Directors. The company emphasizes ethical conduct, product accessibility through programs like AfrezzaAssist, and environmental stewardship at its LEED Silver certified California office and Danbury manufacturing facility. It also details efforts in diversity and inclusion, with 43% of the workforce identifying as female.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees